Caitong International Asset Management’s Indivior Pharmaceuticals INDV Stock Holding History

Caitong International Asset Management’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-61	Closed	-$1.86K	–	3213
2026 Q1	$1.86K	Sell	61 -1,032	-94%	-$34.1K	﹤0.01%	1256
2025 Q4	$39.2K	Buy	1,093 +460	+73%	+$14K	0.01%	795
2025 Q3	$15.3K	Sell	633 -77	-11%	-$1.61K	0.01%	848
2025 Q2	$10.5K	Buy	710 +404	+132%	+$4.71K	0.01%	707
2025 Q1	$2.92K	Buy	306 +255	+500%	+$2.68K	﹤0.01%	1206
2024 Q4	$634	Buy	+51	New	+$525	﹤0.01%	1419

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caitong International Asset Management's INDV Position: Q2 2026 in Review

Caitong International Asset Management sold out of Indivior Pharmaceuticals (INDV) in Q2 2026, closing a stake of 61 shares — an estimated $1.86K sold.

Caitong International Asset Management first reported a position in INDV in Q4 2024 and held it in 6 quarters. The position peaked at $39.2K in Q4 2025. 336 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

Caitong International Asset Management reported no remaining Indivior Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Caitong International Asset Management sold 61 Indivior Pharmaceuticals shares in Q2 2026, an estimated $1.86K.
Caitong International Asset Management first reported a position in Indivior Pharmaceuticals in Q4 2024 and held it in 6 quarters.
Caitong International Asset Management's Indivior Pharmaceuticals position peaked at $39.2K in Q4 2025.
336 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.